@brendanpaul.a's GHK-Cu peptide claims fact-checked

What does this video actually claim?

Brendan warns against making a specific "mistake" when using GHK-Cu and "glow" peptides, though the exact mistake isn't clear from the caption. The video targets women over 40 and moms over 30, suggesting these peptides offer cosmetic benefits for skin aging.

GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a copper-binding tripeptide that's marketed for anti-aging and wound healing. The "glow peptide" reference likely means other cosmetic peptides often stacked with GHK-Cu. Without seeing the full video, we can't verify the specific mistake being referenced.

Does the science actually support GHK-Cu for anti-aging?

The evidence for GHK-Cu in humans is surprisingly thin for such a hyped compound. Most studies showing benefits used topical formulations, not injections. A 2012 study by Pickart et al. in Clinical, Cosmetic and Investigational Dermatology found that 0.05% GHK-Cu cream improved skin firmness by 20% over 12 weeks in 71 women.

But here's the problem: the peptide therapy community largely uses injectable GHK-Cu, which has zero published clinical trials for cosmetic benefits. The bioavailability and tissue distribution of injected versus topical GHK-Cu are completely different. You can't assume topical studies apply to injections.

A 2018 review by Pickart and Margolina noted that oral GHK-Cu supplements showed no measurable increases in plasma copper-peptide levels. This raises questions about whether injected peptides even reach target tissues effectively.

What's the real safety picture here?

Brendan's warning about mistakes is actually worth attention, even if we don't know the specifics. Injectable peptides from research chemical companies aren't FDA-approved and often lack proper sterility testing.

GHK-Cu can cause copper accumulation with repeated use. A 2020 case report in Dermatology Online Journal described copper toxicity from excessive topical copper peptide use, causing liver enzyme elevation. Injectable forms could theoretically pose higher risks.

The bigger issue is that most "peptide therapy" operates in a regulatory gray area. These aren't prescription medications with known dosing, purity, or safety profiles. Women over 40 dealing with hormonal changes might be better served by proven treatments rather than experimental peptides.

What should you actually know about peptide therapy?

The peptide therapy market is full of overblown claims based on limited evidence. While GHK-Cu shows promise in laboratory studies and small topical trials, the leap to injectable anti-aging therapy isn't scientifically justified.

If you're interested in evidence-based anti-aging approaches, retinoids have decades of human data. Tretinoin showed 35% improvement in photodamage scores in a 2007 study by Kang et al. in Archives of Dermatology. That's real data with real oversight.

Brendan gets credit for adding the "informational purposes only" disclaimer, but his audience of moms over 30 deserves to know that peptide therapy is largely experimental. The mistake he's warning about might be valid, but the bigger mistake could be choosing unproven peptides over established treatments.